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Abstract
Background: Indwelling pleural catheters (IPC) are increasingly becoming a first-line treatment in the management
of malignant pleural effusions. Ambulatory management using IPC are increasingly used in this patient group whilst
they are receiving concurrent chemotherapy. There are currently no prospective trials examining IPC safety in
chemotherapy. This study’s objective is to determine if IPC insertion is safe in patients undergoing chemotherapy.
Methods: We conducted a retrospective analysis of all patients who underwent IPC insertion for malignant pleural
effusion at our trust from September 2010 to December 2014. Data was collected on IPC insertion and removal,
tumour type, systemic chemotherapy, pleural infection and other complications.
Results: One hundred four patients were identified, 43 in chemotherapy group and 61 in non-chemotherapy
group. The incidence of pleural infection in chemotherapy group vs non-chemotherapy group, 4 (9.3 %) vs 3
(4.9 %) respectively, was not statistically different (Fisher’s exact p = 0.311). There was no significant difference
in six-month infection-free duration from the date of IPC insertion (log rank p = 0.394). Overall six-month mortality in
chemotherapy group was significantly lower than in non-chemotherapy group (log rank p = 0.007).
Conclusions: This is the second largest retrospective case–control series that concludes systemic chemotherapy is safe
in patients with IPC undergoing chemotherapy.
Keywords: Antineoplastic agents, Catheters, Indwelling, Pleura, Pleural effusion, Malignant
Background
Malignant pleural effusions (MPE) are a common
presentation in the advanced and disseminated stages
of malignancy, complicating nearly 50 % of all lung
and breast cancers [1]. Extrapolated data estimates 50
000 new cases of MPE per year in the UK, translating
to one new case per 1000 population per year [2].
The development of MPE can result in significant
morbidity including disabling breathlessness, pain and
reduced physical capability. Treatment is aimed at re-
lieving breathlessness and improving quality of life.
MPE is associated with a poor prognosis, dependent
on the type and stage of cancer, with a median sur-
vival of only 74 days in lung cancer and less than
50 days in urological cancer, sarcoma and melanoma
groups [3]. Therefore a definitive single pleural inter-
vention is important in a patient group with a poor
prognosis.
If the primary tumour type is particularly sensitive
to chemotherapy, oncological treatment may result in
regression of the effusion and symptom alleviation.
However, the initial presentation of malignancy may
be breathlessness secondary to MPE, which requires
pleural intervention prior to starting chemotherapy.
There are two main therapeutic strategies to palliate
recurrent MPE. The most common strategy is to at-
tempt pleurodesis either via chest drain or by thora-
coscopy. The alternative is continuous drainage with
an indwelling pleural catheter (IPC). Superiority of
one method over the other is not clear [4–6].
The popularity and use of IPC has grown over the last
decade as they permit outpatient ambulatory management
of MPE with low complication rates [7–10]. Although
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conventionally reserved for patients with trapped lung
or previous failed pleurodesis, more recently a novel
pathway of administering talc slurry via the IPC has
been shown to be safe and efficacious [9]. Trials evaluating
IPC as a first line treatment strategy are currently under-
way, including the IPC PLUS trial (UKCRN 73255764) in-
vestigating the success rate of talc pleurodesis via IPC and
the OPTIMUM trial (UKCRN 19615) examining health-
related quality of life outcomes.
There is an associated risk of infection with the
semi-permanent nature of IPC, ranging between 2.2
and 12 % [11, 12]. In current literature, there are no
randomised controlled trials comparing infection rate
in patients with IPC to other pleural interventions
and no prospective trials primarily examining IPC
safety in chemotherapy. Of the published case series
available, there is reportedly no increased risk of in-
fection in patients with IPC undergoing chemotherapy
[13, 14]. Our primary study objective is to determine




This study is a retrospective case–control series. IPC
have been adopted as part of first-line management
pathway for malignant effusions at Guy’s and St Thomas’
NHS Foundation Trust, London, UK, since 2010. We
performed a review of hospital inpatient documentation,
clinic letters, microbiological and biochemical results.
Data collection was conducted over the period of April
to July 2015, on date of IPC insertion and removal (if
known), tumour type, chemotherapy, six-month incidence
of pleural infection and other complication rates, as well
as six-month mortality from date of IPC insertion.
Following consultation with our local Research and
Development department at Guy’s and St Thomas’ NHS
Foundation Trust, we obtained local clinical governance
committee approval for the use of patient records. As a
retrospective service evaluation, written patient informed
consent and regional ethics approval was not required. Pa-
tient identifiable information was not recorded to main-
tain patient confidentiality.
Participants
We included all patients with symptomatic MPE who
underwent IPC insertion between September 2010
and December 2014. Patients with benign disease
were excluded.
Interventions
All procedures were performed on an outpatient basis,
unless the patient had already been admitted to hospital.
We defined chemotherapy intervention as systemic
cytotoxic, molecular or biological therapy, excluding
hormonal therapy.
Assessments
The primary endpoint of this study was pleural infection
whilst an IPC was in-situ. Pleural infection was defined
as, 1) A clinical presentation compatible with pleural in-
fection requiring antibiotic treatment, and 2) A pleural
fluid sample that meets at least one or more of the fol-
lowing criteria:
a. Purulent
b. Gram stain positive for bacteria
c. Bacterial culture positive.
Secondary endpoints were defined as IPC-related cel-
lulitis, pain and drain blockage and six-month mortality
data from the date of IPC insertion.
Statistical analyses were performed using IBM SPSS
version 22. Chi-squared (χ2) or Fishers exact tests
(where indicated) were performed on dichotomous
categorical variables. Log-rank test was used to com-
pare infection-free survival as well as overall survival
between chemotherapy and non-chemotherapy groups.
Survival distributions were depicted by Kaplan-Meier
survival curves.
Results
One hundred four patients underwent IPC insertion for
MPE between September 2010 and December 2014, 43
in chemotherapy group and 61 in non-chemotherapy
group (Table 1).
The incidence of pleural infection at six-month
follow-up in chemotherapy group vs non-chemotherapy
group was 4 (9.3 %) vs 3 (4.9 %) respectively. This was not
statistically different (Fisher’s exact p = 0.311) (Table 2).
Table 1 Patient demographics and interventions
Chemotherapy No chemotherapy
No. of patients 43 (40 %) 61 (60 %)
Mean age (yrs) (SD) 64 (15) 68 (12)
Cancer primary
Lung (Small cell) 0 (0 %) 1 (2 %)
Lung (Non-small cell) 17 (40 %) 16 (26 %)
Mesothelioma 3 (7 %) 9 (15 %)
Breast 11 (26 %) 16 (26 %)
Other 12 (28 %) 19 (31 %)
Median duration IPC
in-situ (days) (IQR)




52 (21–105) (~4 cycles) -
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There was no significant difference in the post-insertion
time to infection between both groups over six-month
follow-up (log rank p = 0.394), where the occurrence of
pleural infection is considered an “event” in the Kaplan-
Meier curve (Fig. 1).
In the seven patients identified with pleural infection
(Table 3), three patients had diagnoses of empyema that
led to drain removal, and two patients (a) had pleural
infection diagnosed within two months of date of death.
Organisms isolated in pleural fluid include: Staphylo-
coccus epidermidis (CoNS), Staphylococcus lugdunesis,
Staphylococcus aureus, Pseudomonas and Enterococcus
faecalis. Only two patients out of 43 in the chemother-
apy group had documented neutropenic sepsis. In one
patient, this occurred after the IPC was removed, and
the second patient was hospitalised with neutropenic
sepsis secondary to pleural infection, was palliated and
died during the same admission.
The incidence of other complications between
chemotherapy and non-chemotherapy groups were
not statistically significant: cellulitis (p = 0.370); pain
(p = 0.550); drain blockage (p = 0.413) (Table 2).
Within the chemotherapy group, each patient under-
went complex individualised regimens often with mul-
tiple chemotherapy types combined or sequentially
(Table 4). As such, no clear association can be made be-
tween type of chemotherapy used and incidence of
pleural infection. Of the four pleural infections in the
chemotherapy group, four different regimes were used,
1: vinorelbine followed by paclitaxel, 2: topetcan
followed by gemcitabine, 3: carboplatin and paclitaxel,
and 4: capcetabine and lapatinib.
Overall six-month mortality in chemotherapy group
(n = 15) was significantly lower than in non-
chemotherapy group (n = 36), 35 % vs 59 % respect-
ively (log rank p = 0.007) (Fig. 2).
Table 2 Complications and mortality
Outcome Chemotherapy Non-chemotherapy Statistical significance
Complications
Pleural infection 4 (9.3 %) 3 (4.9 %) p = 0.311
Cellulitis 2 (4.7 %) 1 (1.6 %) p = 0.370
Pain 2 (4.7 %) 2 (3.3 %) p = 0.550
Drain blockage 1 (2.3 %) 0 (0 %) p = 0.413
6-month mortality 15 (35 %) 36 (59 %) p = 0.007
Fig. 1 Time to pleural infection over six-months between chemotherapy and non-chemotherapy groups (Kaplan-Meier). Event: pleural infection.
Blue line: non-chemotherapy group; Green line: chemotherapy group
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Discussion
IPC are increasingly used to manage malignant
pleural effusions in a heterogeneous population, in-
cluding those receiving chemotherapy. The complica-
tion rate of these devices is low with no significant
difference in adverse events with IPC compared to
chest drain insertion and talc pleurodesis [4].
Our retrospective data shows that there is no in-
creased rate of pleural or skin infection in patients
undergoing chemotherapy compared to the non-
chemotherapy group. These results are supported by
the limited literature available. The largest case series
by Mekhaeil et al. comprised of 262 patients with a
reported pleural infection rate of 5.2 % in the chemo-
therapy group, which was not significantly different
from the non-chemotherapy group [13]. Morel et al.
found similar results [14]. In the TIME2 study of five
serious pleural infections in the IPC group, only one
patient received systemic chemotherapy at the time
[4]. The significant survival benefit found in the
chemotherapy group is reassuring. In our population,
32.7 % of patients survived less than three months
and 12.5 % survived less than one month from the
date IPC insertion. Similarly, a third of patients re-
cruited into the TIME2 study died within three
months (despite an exclusion criteria for trial entry of
predicted survival of < three months) [4]. Although
clinical trials investigating MPE aim to recruit pa-
tients with a reasonable prognosis, in practice, IPC
are not being exclusively used in this patient group.
There is a lack of consensus on a “safe” window for
IPC insertion, particularly in the context of chemo-
therapy. In our practice, we consider neutropenia,
thrombocytopaenia or irreversible anticoagulation or
coagulopathy as contraindications to IPC implant-
ation, and would delay IPC insertion until these have
recovered. With increasingly complex chemotherapy
regimes and targeted therapies, close liaison with on-
cologists is vital for a positive patient outcome.
The main limitation of this study is that given ad-
verse events are a rare occurrence, our study may not
be sufficiently powered to detect a difference. The re-
lationship between chemotherapeutic agent and inci-
dence of pleural infection was not our primary
endpoint and requires further evaluation. Although a
retrospective analysis, our open inclusion criteria
should prevent any bias that may affect the selection
of controls. The strength of our data is in its applica-
tion in everyday practice.
There is a clear need for further prospective study
to examine the safety of IPC insertion and longer-
term use in patients with MPE undergoing chemo-
therapy. Important prospective evidence as secondary
outcomes are likely to be obtained from the IPC
PLUS (UKCRN 73255764) and the OPTIMUM trials
(UKCRN 19615), which should provide the data
needed. Given the increasing use of IPC worldwide,
international collaboration with a prospective database
will allow the pooling of long-term outcomes.
Conclusions
This is the second largest retrospective case–control
series that advocates the safety of IPC insertion as a
first-line treatment for malignant effusion. Our data
suggests that patients undergoing chemotherapy should
not be denied ambulatory management of their effusion
with an IPC.
Table 3 Pleural infection details




Organisms isolated IPC removed due
to empyema
1a No Yes Yes Yes Staphylococcus lugdunesis Yes
2 No No No No - Yes
3 No Yes Yes No - No
4 Yes No No Yes Staphylococcus epidermidis (CoNS) No
5 Yes No Yes Yes Staphylococcus epidermidis (CoNS) No
6a Yes No No Yes Staphylococcus aureus No
7 Yes Yes Yes Yes Pseudomonas, Enterococcus faecalis Yes
aPatients with pleural infection diagnosed within two months of date of death
Table 4 Chemotherapy types




EGFR/TKI inhibitors 8 1
Biologics 5 0
Topoisomerase inhibitors 1 1
Vinca alkaloids 1 1
Anthracyclines 1 0
aChemotherapy type counted individually if part of multi-agent regime in the
same patient
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